Cancer research has revealed proteins known to play a role in the disease, but with no known way of stopping what they do. In pharmaceutical parlance, they’re “undruggable.”
Revolution Medicines is trying to drug the undruggable with small molecules that block... Read more »
Perhaps the most talked-about news at the JP Morgan Healthcare Conference this week was a new startup that launched with $200 million and an ambitious claim that its first drug would be approved within five years, and 10 in total within... Read more »
Neon Therapeutics closed 2019 by curtailing its cancer vaccine programs and laying off 24 percent of its workforce, part of a corporate restructuring aimed at finding a new path for the company. That new path will now be as a division... Read more »
We’re excited to announce the first in Xconomy’s new Xcelerating Life Sciences event series convening local communities of innovators, executives, rising pioneers, entrepreneurs, investors, and scientists: Xcelerating Life Sciences San Diego will help you stay at the forefront of San Diego’s... Read more »
Startup nference has closed a $60 million Series B financing round to expand the use of its augmented intelligence platform in clinical research and drug development.
Mayo Clinic and NTT Venture Capital joined previous investors Matrix Partners and Matrix Capital Management,... Read more »
Emendo Biotherapeutics, a company aiming to apply CRISPR gene editing to a wider range of genetic diseases, has raised $61 million in financing.
The Series B round was led by AnGes, a Japan-based biopharmaceutical company.
New York-based Emendo did not respond... Read more »
The Department of Defense has awarded Adaptive Phage Therapeutics a $10.2 million contract to help advance its experimental therapy for the treatment of multidrug-resistant infections.
Gaithersburg, MD-based Adaptive Phage Therapeutics (APT) says it will pursue a two-year multi-site clinical trial as... Read more »
[Updated 1/15/2020, 8:51 a.m. See below.] As the nation grapples with the ongoing opioid crisis, an FDA advisory panel on Tuesday unanimously voted against recommending approval of a Nektar Therapeutics painkiller that would add a new compound to the... Read more »
Insilico Medicine on Tuesday announced that it has entered a research collaboration with Pfizer, which Insilico CEO Alex Zhavoronkov says has “one of the most advanced AI teams internally both in target identification and chemistry.”
Under the agreement, Pfizer (NYSE: PFE... Read more »
Scan the landscape of experimental medicines in development today and you’ll spot Schrödinger’s handiwork. The company’s software has helped discover compounds that are now advancing in the pipelines of several drug developers.
Schrödinger isn’t shying away from that work. But as... Read more »
Daré Bioscience launched in 2015 with the aim of assembling a portfolio of novel women’s health products intended to pique interest from major pharmaceutical companies.
Now the San Diego-based company has inked its first deal with Big Pharma, signing an agreement... Read more »
The genetic testing company NeoGenomics has acquired Human Longevity’s oncology division, which provides next-generation sequencing services.
The division of San Diego-based Human Longevity generated approximately $10 million in revenue in 2019—an amount NeoGenomics (NASDAQ: NEO) thinks it can grow by... Read more »
Continuing to make headlines in the neurodegenerative disease space, Biogen on Monday announced a deal to acquire a clinical-stage Pfizer asset that has potential applications in Alzheimer’s and Parkinson’s disease, for $75 million.
Cambridge, MA-based Biogen (NASDAQ: BIIB) could end... Read more »